BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 7962325)

  • 1. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
    Barnes RB; Rosenfield RL; Ehrmann DA; Cara JF; Cuttler L; Levitsky LL; Rosenthal IM
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1328-33. PubMed ID: 7962325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Source localization of androgen excess in adolescent girls.
    Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of functional ovarian hyperandrogenism in women with androgen excess.
    Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
    N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
    J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency.
    Barnes RB; Ehrmann DA; Brigell DF; Rosenfield RL
    J Clin Endocrinol Metab; 1993 Feb; 76(2):450-5. PubMed ID: 8381802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone.
    Goodarzi MO; Dawson DW; Li X; Lei Z; Shintaku P; Rao CV; Van Herle AJ
    J Clin Endocrinol Metab; 2003 Jan; 88(1):73-7. PubMed ID: 12519832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
    Bidzińska B; Tworowska U; Demissie M; Milewicz A
    Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome.
    Goudas VT; Dumesic DA
    Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
    Rosenfield RL; Ehrmann DA; Barnes RB; Sheikh Z
    Ann N Y Acad Sci; 1993 May; 687():162-81. PubMed ID: 8323171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirsutism and virilism in women.
    Kirschner MA
    Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone pulsatility in patients with major ovarian hyperandrogenism.
    Bachelot A; Laborde K; Bresson JL; Plu-Bureau G; Raynaud A; Bertagna X; Mogenet A; Mansour M; Lucas-Jouy V; Gayno JP; Reznik Y; Kuhn JM; Billaud L; Vacher-Lavenu MC; Putterman M; Mowszowicz I; Touraine P; Kuttenn F
    J Endocrinol Invest; 2007 Sep; 30(8):636-46. PubMed ID: 17923794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperandrogenism in premenopausal women].
    Pugeat M
    Rev Fr Gynecol Obstet; 1990 Feb; 85(2):85-90. PubMed ID: 2181598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
    Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
    Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal hyperandrogenism.
    Yoldemir T
    Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
    Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
    N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperandrogenism in peripubertal girls.
    Rosenfield RL
    Pediatr Clin North Am; 1990 Dec; 37(6):1333-58. PubMed ID: 2259543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.